1. Introduction {#sec1}
===============

People with Down syndrome (DS), or trisomy 21, have an exceptionally high risk to develop Alzheimer\'s disease (AD): 68%--80% of people are diagnosed with dementia by the age of 65 years [@bib1]. The additional copy of chromosome 21, encoding the amyloid precursor protein (APP), causes overproduction of amyloid β (Aβ) peptides. Very early in life, intracellular Aβ accumulation takes place in neurons, followed by extracellular Aβ aggregation and subsequent deposition in characteristic Aβ plaques [@bib2], [@bib3], [@bib4], [@bib5]. In DS brains, not only plaques but also neurofibrillary tangles are omnipresent from the age of 40 years [@bib6]. The onset of clinical dementia symptoms, however, is subject to a marked variation in time [@bib7], [@bib8]. Because the dementia diagnosis in DS is complex, among others due to comorbidities, pre-existing intellectual disability, and behavior [@bib9], sensitive and specific biomarkers for AD in DS would be very valuable. In the general non-DS population, the so-called "AD profile" (low Aβ42, high total-tau, and high phosphorylated-tau) in cerebrospinal fluid (CSF) has proven useful as a diagnostic aid [@bib10]. However, the clinical utility in DS has not been demonstrated yet [@bib11]. Therefore, the study of alternative biomarkers for AD in DS receives vast attention.

In this context, we previously analyzed monoamine neurotransmitters and metabolites in serum of 151 elderly DS individuals with AD (DS+AD) and without AD (DS), but also in a nondemented DS group at blood sampling that developed dementia over time (converters). Remarkably, serum levels of the primary noradrenergic metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) were strongly decreased in DS+AD, but also in converted DS individuals. Individuals with MHPG levels below median had a more than 10-fold increased risk of developing dementia, suggesting that decreased serum MHPG levels may be predictive for conversion to AD [@bib12].

Blood biomarkers, however, are subject to (confounding) peripheral effects. CSF biomarkers are generally regarded better indicators of biochemical changes in the central nervous system because of their direct contact with the extracellular space [@bib13]. Very few studies have investigated CSF biomarkers in (moreover small) DS cohorts [@bib11], including two on monoamines [@bib14], [@bib15]. Although a few postmortem studies were conducted several decades ago, a comprehensive profile of central monoaminergic changes in DS+AD is not established yet. Indeed, monoamines were quantified in a limited number of brain regions from a few DS cases with often long postmortem delays (PMDs). For instance, cell loss in the locus coeruleus (LC), major source of noradrenaline (NA), and reduced NA concentrations have been reported in elderly DS cases [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], but an integrated study of regional changes in NA, dopamine (DA), serotonin (5-HT), and their primary metabolites is lacking. Vermeiren et al., for example, investigated monoaminergic profiles in a variety of postmortem brain regions in early-onset AD patients (EOAD) compared with age- and gender-matched control subjects. In EOAD patients, lower levels of serotonergic compounds were found in amygdala and hippocampus, complemented by lower NA levels in the prefrontal cortex and amygdala. No differences in MHPG levels could be observed [@bib24].

To the best of our knowledge, this study is the first to comprehensively evaluate monoaminergic alterations in (1) postmortem brain tissues and (2) (paired) CSF/plasma samples from DS individuals with and without AD. Noradrenergic (NA; adrenaline; MHPG), dopaminergic (DA; 3,4-dihydroxyphenylacetic acid \[DOPAC\]; homovanillic acid \[HVA\]), and serotonergic (5-HT; 5-hydroxyindoleacetic acid \[5-HIAA\]) compounds were quantified using reversed phase high-performance liquid chromatography (RP-HPLC). In one of the largest collections of DS brain tissue (n = 21), 15 regions of DS cases without and with a neuropathologically confirmed diagnosis of AD (DS and DS+AD, respectively) were analyzed and compared with EOAD patients and healthy controls in the general population. Second, we report the monoaminergic results in (paired) CSF/plasma samples obtained from the largest DS cohort to have undergone lumbar punctures, comparing DS without dementia (DS), DS with prodromal AD (DS+pAD), and DS with clinically diagnosed AD (DS+AD).

2. Materials and methods {#sec2}
========================

2.1. Postmortem samples {#sec2.1}
-----------------------

### 2.1.1. Study population {#sec2.1.1}

In total, postmortem samples from 21 elderly DS individuals were obtained from the Netherlands Brain Bank (NBB), Netherlands Institute for Neuroscience (Amsterdam, The Netherlands), the Neurological Tissue Bank---Biobanc, Hospital Clinic Barcelona---Institut d\'Investigacions Biomediques August Pi i Sunyer (IDIBAPS; Barcelona, Spain), and the Institute Born-Bunge (IBB; Antwerp, Belgium). Specifically, brain samples from nine DS+AD individuals were obtained from the NBB (open access: [www.brainbank.nl](http://www.brainbank.nl){#intref0010}). All material has been collected from donors for or from whom written informed consent for a brain autopsy and the use of the material and clinical information for research purposes had been obtained by the NBB. Moreover, the IDIBAPS provided samples of two DS and five DS+AD donors for whom written informed consent was obtained from the next of kin. The study was approved by the Hospital Clinic de Barcelona Ethics Committee and in accordance with Spanish legislation. Finally, the IBB provided samples of DS (n = 2), DS+AD (n = 3), EOAD patients (n = 11), and healthy controls without neurological disease (n = 10). Since DS+AD presents early in life, we identified EOAD patients and controls \<75 years of age as comparison groups. Ethical approval was granted by the medical ethics committee of the Hospital Network Antwerp (ZNA, approval numbers 2805 and 2806). The study was compliant with the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects.

### 2.1.2. Assessment of AD neuropathologic changes {#sec2.1.2}

Neuropathological analysis was conducted according to the "ABC scoring" system [@bib25]. Formalin-fixed paraffin-embedded samples were sectioned in concordance with the minimally recommended brain regions (if available). If possible, additional sections of the cingulate gyrus, amygdala, pons at the level of the LC, and medulla oblongata were included. Applied stains were hematoxylin-eosin, cresyl violet, Klüver-Barrera (myelin), and modified Bielschowsky silver staining. Moreover, antibodies against amyloid (4G8), phosphorylated-tau (AT8), ubiquitin, TDP-43, and p62 Lck ligands were used. All cases were diagnosed by experienced neuropathologists (E.G., A.S., and J.-J.M.) as not, low, intermediate, or high AD neuropathologic changes. Intermediate and high signify the diagnosis of AD [@bib25].

### 2.1.3. Regional brain samples and dissection {#sec2.1.3}

[Table 1](#tbl1){ref-type="table"} shows the selection of frozen samples for RP-HPLC analyses. Brains were included in the three biobanks between 1990 and 2011 and stored at −80°C. Postmortem delays: NBB (\<10 hours), IDIBAPS (\<12 hours), and IBB (DS: 20 and 36 hours; DS+AD: 15 hours, 20 hours, and one unknown; and EOAD/controls: \<7 hours). Samples were dissected from the left hemispheres (undefined hemisphere for three IBB cases). Not all regions were available for all cases. Most samples from EOAD and controls have been published before [@bib24]. For this study, Brodmann area (BA)7, substantia nigra (SN), caudate nucleus, globus pallidus, and putamen were additionally analyzed.Table 1Characteristics of postmortem study groupsCharacteristicsDS (n = 4)DS+AD (n = 17)EOAD (n = 11)Controls (n = 10)*P* valueAge at death in years (median; min.−max.)39.5 (35.0--44.0)^a,b,c^62.0 (44.0--80.0)^a^67.2 (57.6--73.0)^b^65.5 (57.2--73.3)^c^.004Gender (N male and %)2 (50)5 (29.4)8 (72.7)6 (60)n.s.Psychoactive medication (yes/no/not reported)3/0/110/3/43/8/02/8/0.002Postmortem delay in hours (median; min.--max.)21.0 (11.5--36.0)^a,b,c^7.3 (3.8--20.0)^a,b,e^3.0 (2.8--7.0)^b,d^5.4 (2.3--7.0)^c,e^\<.001AD neuropathologic changeLowHighIntermediate (1)/High (10)Not (6)/Low (4)Available brain regions per study group Neocortex BA7: superior parietal lobule2131110 BA9/10/46: (pre)frontal cortex4141110 BA17: occipital pole (V1)371110 BA22: superior temporal gyrus3101110 Limbic system Amygdala2101010 Hippocampus351110 BA11/12: orbitofrontal cortex461110 Cingulate gyrus381110 Thalamus3111110 Basal ganglia Caudate nucleus3161110 Globus pallidus281110 Putamen3151110 Substantia nigra2141110 Metencephalon Locus coeruleus (in pons)--101010 Cerebellar cortex291010[^1][^2]

2.2. CSF/plasma samples {#sec2.2}
-----------------------

Samples of 241 DS adults were obtained from the Down Alzheimer Barcelona Neuroimaging Initiative study, a prospective biomarker study for AD in DS [@bib26], [@bib27], [@bib28]. The person with DS and/or the legal representative provided written informed consent. The study was compliant with the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects and approved by the ethics committee of the Sant Pau hospital in Barcelona [@bib27]. Neurologists and neuropsychologists established a consensus diagnosis of dementia, distinguishing between DS without dementia (DS), DS with prodromal AD (DS+pAD), and DS with diagnosed AD (DS+AD). Specifically, the DS group did not show evidence of cognitive decline. The DS+pAD group includes individuals who (1) presented cognitive/functional change but did not (yet) meet criteria for dementia or (2) showed significant cognitive decline in longitudinal assessment. The DS+AD group includes individuals with clear cognitive/functional change meeting the dementia criteria (IWG-2 [@bib29]). In the diagnostic procedure, medical comorbidities and other possible causes of cognitive decline were assessed (differential diagnostics). DS cases with cognitive decline due to medical comorbidities or a psychiatric etiology were excluded ([Fig. 1](#fig1){ref-type="fig"}). Use of psychoactive medication around the moment of sampling was noted. Within the Down Alzheimer Barcelona Neuroimaging Initiative study, participants are offered a lumbar puncture, which was found to be feasible and safe [@bib27]. For 68 individuals, paired CSF/plasma samples were obtained. The other 157 participants provided plasma-only. CSF and plasma samples were drawn on the same day. Lumbar punctures were performed between 9 and 12 am, directly followed by plasma collection. Samples were stored at −80°C.Fig. 1Flow chart of CSF/plasma study groups. Abbreviations: AD, Alzheimer\'s disease; CSF, cerebrospinal fluid; DS, Down syndrome without (clinical) dementia; DS+AD, DS with diagnosed AD dementia; DS+pAD, Down syndrome with prodromal AD.

2.3. Reversed-phase HPLC {#sec2.3}
------------------------

To quantify noradrenergic (NA; adrenaline; MHPG), dopaminergic (DA; DOPAC; HVA), and serotonergic (5-HT; 5-HIAA) compounds, a validated RP-HPLC setup with ion pairing (octane-1-sulfonic acid sodium salt) and amperometric electrochemical detection was used [@bib30], previously applied to CSF and blood samples [@bib12] and brain homogenates [@bib24], [@bib31], [@bib32], [@bib33]. Concentrations were calculated using Clarity Software (DataApex Ltd., 2008, Prague, Czech Republic).

2.4. Statistics {#sec2.4}
---------------

Histograms, normal quantile-quantile (Q-Q) plots, and Shapiro-Wilk tests (*P* \< .05) demonstrated that the concentrations in the brain and CSF/plasma were (largely) not normally distributed. Consequently, nonparametric Kruskal-Wallis tests were applied to compare groups. If the *P* value was \<.05, post hoc Mann-Whitney *U* tests were conducted. In brain, the three most relevant group comparisons were performed: DS versus DS+AD, DS+AD versus EOAD, and DS versus controls. The EOAD versus controls comparison has been largely published before [@bib24]. Regarding CSF/plasma samples, we analyzed the total cohort (n = 225), that is, all individuals regardless of medication use, as well as the medication-free subpopulation because psychoactive medication may affect monoaminergic neurotransmission. Nonparametric Spearman\'s rank-order correlation tests established the relationship with age and between CSF and plasma concentrations. Cohort characteristics like gender and medication use were compared using Pearson\'s χ^2^ tests or Fisher\'s exact tests. To account for multiple comparisons, we applied the Benjamini-Hochberg procedure with a false discovery rate of 0.05 [@bib34]. Original *P* values \<.015 were regarded significant. Finally, we evaluated whether the results in the brain were possibly affected by psychoactive medication and PMDs. Within each group, we performed Mann-Whitney *U* tests to compare monoaminergic concentrations between those taking psychoactive medication and a subgroup that did not and performed Spearman\'s rank-order correlation tests to establish the association between PMDs and monoaminergic concentrations. IBM SPSS Statistics, version 23.0, was used.

3. Results {#sec3}
==========

Based on the measured concentrations, five accompanying ratios were calculated: (1) MHPG:NA (noradrenergic turnover), (2) DOPAC:DA (dopaminergic turnover) and (3) HVA:DA (dopaminergic turnover), (4) 5-HIAA:5-HT (serotonergic turnover), and (5) HVA:5-HIAA (serotonergic inhibition on dopaminergic neurotransmission).

3.1. Monoaminergic characterization of postmortem brain tissue {#sec3.1}
--------------------------------------------------------------

[Table 1](#tbl1){ref-type="table"} shows the general demographics, use of psychoactive medication, and PMDs for each of the four groups. [Table 2](#tbl2){ref-type="table"} provides the monoaminergic concentrations (median and quartiles) that differed significantly between the groups. Specifically, DS versus DS+AD, DS+AD versus EOAD, and DS versus controls were compared. EOAD and controls were used as the reference group (compared in [@bib24], thus not further described here). The supplementary material provides all concentrations and the accompanying ratios for noradrenergic ([Supplementary Table 1](#appsec1){ref-type="sec"}), dopaminergic ([Supplementary Table 2](#appsec1){ref-type="sec"}), and serotonergic ([Supplementary Table 3](#appsec1){ref-type="sec"}) systems.Table 2Comparison of postmortem concentrations between the groupsBrain regionCompoundNDS (n = 4)DS+AD (n = 17)EOAD (n = 11)Controls (n = 10)*P* valueNeocortex BA7MHPG2/13/11/1071.0 (63.3--)72.3 (57.0--105.2)\*119.4 (106.0--189.5)\*259.7 (119.8--354.5)\<.001DA2/12/11/1011.0 (6.5--)18.7 (12.5--28.7)10.7 (6.4--16.5)6.9 (4.5--9.9).0045-HIAA2/13/11/1092.8 (70.4--)40.2 (30.4--71.1)55.3 (40.5--93.7)106.4 (75.3--158.9).003 BA9/10/46MHPG4/14/11/1084.2 (77.7--86.9)107.4 (63.4--133.8)\*\*471.2 (284.3--655.1)\*\*265.7 (132.4--629.6)\<.001DA4/14/11/10127.5 (11.4--497.4)373.9 (204.3--743.6)\*\*7.2 (2.5--9.3)\*\*7.5 (4.0--11.3)\<.0015-HT4/14/11/1017.8 (13.2--30.6)28.7 (15.3--49.8)\*11.1 (6.1--15.0)\*11.7 (7.4--16.7).0095-HIAA4/14/11/1081.1 (64.6--122.2)62.2 (33.9--87.4)\*144.7 (110.5--186.6)\*164.1 (128.2--215.6).001 BA17MHPG3/7/11/1077.2 (61.3--)\#89.2 (73.6--114.6)127.9 (101.6--182.0)285.3 (244.0--530.1)\#\<.0015-HIAA3/7/11/10126.0 (93.6--)92.1 (46.9--144.1)95.6 (57.5--143.6)200.8 (154.3--263.9).008 BA22NA3/10/9/1030.2 (18.3--)17.3 (12.5--27.4)10.0 (7.4--12.4)18.7 (13.6--28.5).014MHPG3/10/11/10107.3 (80.4--)\#87.0 (60.0--125.4)\*\*520.7 (313.4--673.4)\*\*360.5 (260.4--630.7)\#\<.001DA3/10/11/106.7 (6.5--)11.3 (8.1--25.2)\*4.2 (3.2--6.8)\*9.1 (5.4--18.4)*.041*5-HIAA3/10/11/10119.1 (98.7--)84.0 (60.4--131.7)\*303.2 (119.6--450.2)\*171.5 (121.7--320.6).004Limbic system AmygdalaNA2/10/10/1021.8 (19.5--)25.3 (13.6--39.8)\*59.0 (46.9--78.5)\*84.5 (77.5--121.8)\<.001MHPG2/10/10/1068.8 (58.2--)70.9 (62.5--94.9)\*\*429.8 (180.0--964.3)\*\*304.8 (193.5--759.3)\<.001HVA2/10/10/10265.8 (174.5--)376.2 (258.9--617.2)599.1 (398.7--866.2)1132.5 (751.0--1421.4).0055-HT2/10/10/1059.3 (11.7--)33.0 (18.6--49.6)\*121.1 (55.1--148.6)\*244.9 (221.7--297.2)\<.0015-HIAA2/10/10/10197.9 (162.9--)141.3 (102.8--227.1)\*\*522.4 (334.9--795.2)\*\*999.8 (754.5--1270.4)\<.001 HippocampusAdrenaline2/5/3/5391.6 (236.5--)42.3 (20.6--139.0)6.4 (2.6--)10.1 (6.4--14.1).011MHPG3/5/11/1075.9 (70.3--)\#97.2 (76.9--124.8)\*\*459.5 (193.2--1099.2)\*\*416.3 (232.9--713.5)\#\<.0015-HT3/5/11/1046.6 (28.0--)13.5 (8.6--50.0)44.4 (20.7--65.3)87.8 (69.3--111.2).0035-HIAA3/5/11/10141.3 (110.6--)47.7 (43.1--213.4)\*336.1 (257.8--476.2)\*383.9 (279.5--717.0).004 BA11/12MHPG4/6/11/1091.8 (70.6--105.7)\#103.1 (63.9--111.2)\*\*437.1 (352.6--545.6)\*\*361.7 (216.5--636.3)\#\<.0015-HIAA4/6/11/1098.2 (85.4--189.7)56.7 (35.3--78.5)\*\*238.5 (183.5--344.3)\*\*229.9 (168.9--328.3)\<.001 Cingulate gyrusMHPG3/8/11/10128.0 (58.8--)126.0 (104.6--153.6)\*\*567.8 (258.4--739.3)\*\*336.9 (158.1--587.5)\<.001DA3/8/11/10224.2 (7.9--)55.5 (40.6--211.2)\*\*10.5 (3.8--13.0)\*\*9.6 (3.0--17.4)\<.0015-HIAA3/8/11/1066.0 (34.5--)\#102.6 (58.5--191.8)\*\*357.3 (281.2--379.3)\*\*387.2 (313.7--475.7)\#\<.001 ThalamusMHPG3/11/11/10159.2 (131.3--)\#148.3 (110.2--177.8)\*\*793.0 (628.6--1442.6)\*\*441.9 (244.1--1345.4)\#\<.0015-HIAA3/11/11/10673.7 (508.8--)689.3 (412.4--895.8)\*\*1584.5 (1237.1--1952.8)\*\*1525.8 (1168.1--1946.8)\<.001Basal ganglia Caudate nucleusAdrenaline2/11/7/6533.3 (355.2--)69.3 (42.7--151.0)\*268.5 (176.5--587.7)\*372.9 (185.7--743.0).006DA3/16/11/104297.2 (1845.8--)2395.2 (1178.5--2784.8)\*\*4721.2 (3403.8--6905.9)\*\*3965.1 (2987.2--4420.5).003HVA3/16/11/102732.0 (2231.3--)3145.6 (1522.7--3756.0)\*4681.2 (3714.5--5640.3)\*4372.3 (3564.4--6818.8).0145-HT3/16/11/10121.5 (33.1--)55.8 (35.6--97.0)\*\*168.3 (139.5--230.2)\*\*240.0 (188.0--285.2)\<.0015-HIAA3/16/11/10170.9 (76.6--)217.6 (106.3--284.2)\*\*537.2 (362.3--727.8)\*\*579.6 (441.0--784.9)\<.001 Globus pallidusDOPAC2/8/11/10208.3 (28.0--)131.7 (61.8--141.5)\*39.5 (19.5--85.8)\*20.1 (10.5--34.7).0045-HT2/8/11/10149.7 (89.7--)97.4 (70.5--120.4)\*171.9 (117.6--207.7)\*161.8 (140.3--215.5)*.022*5-HIAA2/8/11/101009.2 (384.6--)439.5 (329.9--978.8)\*984.5 (864.7--1407.3)\*1320.2 (1019.2--1614.4)*.015* PutamenAdrenaline2/8/11/10390.4 (325.6)135.0 (40.9--219.9)\*581.9 (187.2--1523.4)\*339.6 (100.7--797.8)*.038*DOPAC3/15/11/10207.5 (165.1--)611.6 (274.7--851.6)421.9 (235.7--625.7)202.2 (119.0--299.7).0085-HT3/15/11/10189.5 (43.9--)77.8 (35.2--159.6)\*189.2 (153.9--219.8)\*219.7 (200.5--326.3)\<.0015-HIAA3/15/11/10260.0 (231.7--)372.7 (203.7--669.5)\*\*790.9 (638.7--1026.1)\*\*998.4 (781.9--1400.3)\<.001 Substantia nigraDA2/14/11/10164 (126.8--)157.2 (89.0--292.4)\*\*572.7 (284.9--623.7)\*\*624.0 (295.7--936.8)\<.001DOPAC2/14/11/1047.2 (47.1--)58.0 (27.1--87.4)\*189.7 (80.3--211.0)\*47.1 (29.2--101.0).005HVA2/14/11/103061.7 (2010.5--)2421.8 (1995.7--3007.8)\*\*3799.4 (3461.0--4385.5)\*\*4331.0 (3241.6--5349.9)\<.0015-HT2/14/11/10208.3 (167.6--)364.1 (243.1--420.4)487.2 (389.2--531.2)461.0 (404.1--588.8).009Metencephalon Locus coeruleusNA0/10/10/10--88.6 (52.7--11.4)\*\*255.1 (171.9--400.7)\*\*347.3 (248.6--501.8)\<.001MHPG0/10/10/10--201.8 (151.8--259.5)\*429.6 (304.6--530.7)\*572.4 (158.9--836.2)*.032*DOPAC0/10/10/10--12.3 (8.1--19.2)\*\*39.0 (23.6--71.3)\*\*55.5 (33.1--98.6)\<.001HVA0/10/10/10--730.2 (482.0--1003.5)1009.7 (905.7--1443.4)1351.0 (1195.0--1482.2)\<.001 CerebellumAdrenaline0/7/4/6--36.4 (34.7--44.5)\*6.6 (3.6--12.7)\*21.4 (10.3--50.2)*.017*MHPG2/9/11/10124.6 (100.3--)101.1 (85.2--148.6)\*421.1 (232.5--708.2)\*518.1 (386.8--713.4).001DA2/9/11/1032.1 (8.4--)15.5 (12.2--22.1)\*\*3.6 (1.5--8.6)\*\*3.6 (3.2--5.4)\<.001DOPAC2/9/11/1035.1 (6.4--)16.4 (11.3--26.8)\*8.2 (5.8--11.1)\*8.0 (6.0--8.3).0055-HT2/9/11/1066.5 (22.2--)25.0 (14.5--34.9)\*\*4.6 (2.1--9.1)\*\*2.6 (2.3--6.8)\<.0015-HIAA2/9/11/1030.8 (21.9--)41.7 (33.8--56.5)\*\*206.0 (92.8--301.4)\*\*98.5 (73.7--207.2)\<.001[^3][^4]

Since psychoactive medication may affect monoaminergic concentrations, we assessed the donors\' clinical documentation ([Table 1](#tbl1){ref-type="table"}). Comparing individuals who did and did not use psychoactive medication within each group yielded no significant monoaminergic differences in DS+AD and control groups, whereas only a single significant difference was found in the EOAD group: NA levels in the caudate nucleus were lower in individuals using medication (*P* = .014). In the DS group, the effect of medication could not be established: three in four used medication, and for the last person, it was unknown. Nevertheless, the use of psychoactive medication did not appear to have evidently impacted monoaminergic concentrations in DS+AD, EOAD, and control groups.

Given the very limited availability of postmortem DS tissue, it was impossible to select for short PMDs, particularly in the DS group. Apart from three cases, PMD was \<12 hours in the DS+AD group. Because PMDs differed between groups ([Table 1](#tbl1){ref-type="table"}), we subsequently examined whether PMD was associated with monoaminergic concentrations. Spearman\'s rank-order correlation tests within each group revealed few significant associations with PMDs: HVA (cingulate gyrus, r = −0.90, *P* = .002) in the DS+AD group; MHPG (caudate nucleus, r = 0.85, *P* = .001 and SN, r = 0.91, *P* \< .001), DA (BA11/12, r = 0.74, *P* = .01), HVA (BA9/10/46, r = 0.80, *P* = .003; BA22, r = 0.88, *P* \< .001; BA11/12, r = 0.91, *P* \< .001; hippocampus, r = 0.86, *P* = .001; thalamus, r = 0.75, *P* = .007; and cerebellum, r = 0.78, *P* = .004) in the EOAD group; and 5-HT in the globus pallidus (r = −0.85, *P* = .002) in the control group. Although the PMD range was the largest in the DS+AD group, most significant correlations were observed in the EOAD group with overall lower PMDs (range: 2.8--7 hours). Although an effect of PMDs cannot be ruled out, our main findings do not appear to be evidently affected by PMDs.

### 3.1.1. Noradrenergic system {#sec3.1.1}

Between groups, NA differed significantly in the BA22, amygdala, and LC. Specifically, NA levels were not altered between DS and DS+AD, but lower in DS+AD compared with EOAD (amygdala and LC, [Table 2](#tbl2){ref-type="table"}). This pattern was more pronounced for MHPG ([Fig. 2](#fig2){ref-type="fig"}). Compared with EOAD, DS+AD presented significantly lower MHPG levels in the LC, cortical (BA7, BA9/10/46, and BA22) and limbic projection areas (amygdala, hippocampus, BA11/12, cingulate gyrus, and thalamus), and cerebellum. Consequently, the MHPG:NA ratio was consistently lower in DS+AD (BA9/10/46, BA22, hippocampus, BA11/12, cingulate gyrus, thalamus, and cerebellum), indicating a reduced noradrenergic turnover. Moreover, MHPG was significantly lower in DS compared with controls ([Fig. 2](#fig2){ref-type="fig"}) for BA17, BA22, hippocampus, BA11/12, and thalamus. Neither NA nor MHPG levels differed significantly in the basal ganglia, whereas adrenaline levels were lower in the caudate nucleus and putamen and higher in the cerebellum in DS+AD (vs. EOAD). Taken together, the noradrenergic system---particularly MHPG---was strongly impaired in DS (vs. controls) and DS+AD (vs. EOAD).Fig. 2MHPG concentrations (ng/g tissue) for each study group in neocortical areas, the limbic system, locus coeruleus, and cerebellum. The boxes represent the IQR (25%--75%) with the black horizontal line indicating the median. The whiskers indicate values within 1.5 IQR. Mild outliers (1.5--3 IQR) are indicated with an open circle, whereas extreme outliers (\>3 IQR) with an asterisk. One extreme value (EOAD, MHPG concentration in hippocampus of 3806 ng/g tissue) is not shown with respect to scaling. Evidently, MHPG levels were consistently lower in DS (vs. controls) and DS+AD (vs. EOAD). DS vs. DS+AD did not differ significantly. Individual comparison statistics are provided in [Table 2](#tbl2){ref-type="table"}. Abbreviations: BA, Brodmann area; DS, Down syndrome without neuropathologic AD diagnosis; DS+AD, Down syndrome with neuropathologic AD diagnosis; EOAD, early-onset Alzheimer\'s disease; IQR, interquartile range; MHPG, 3-methoxy-4-hydroxyphenylglycol.

### 3.1.2. Dopaminergic system {#sec3.1.2}

No significant differences were observed for DS versus DS+AD and DS versus controls. Compared with EOAD, bidirectional dopaminergic changes became evident in DS+AD: DA levels were significantly higher in the BA9/10/46, BA22, cingulate gyrus, and cerebellum and lower in the basal ganglia (caudate nucleus and SN). Similarly, in DS+AD (vs. EOAD), HVA was reduced in the caudate nucleus and SN. Consequently, the HVA:DA ratio, indicative of dopaminergic turnover, was consistently lower in DS+AD (vs. EOAD) in cortical areas (BA7, BA9/10/46, and BA22), limbic regions (BA11/12, cingulate gyrus, and thalamus), and the cerebellum. In contrast, the HVA:DA ratio was increased in the SN. The pattern for DOPAC was bidirectional as well: values were decreased in the SN and LC and increased in the globus pallidus and cerebellum. The DOPAC:DA ratio was significantly lower in the BA9/10/46, BA22, cingulate gyrus, and LC for DS+AD versus EOAD. In short, the dopaminergic system was evidently affected in DS+AD with higher DA levels (and thus lower HVA:DA and DOPAC:DA ratios) in cortical areas, limbic regions, and the cerebellum and lower DA and HVA levels in the basal ganglia.

### 3.1.3. Serotonergic system {#sec3.1.3}

5-HT and 5-HIAA did not differ significantly between DS and DS+AD. 5-HIAA levels in the cingulate gyrus and the 5-HIAA:5-HT ratio in the (pre)frontal cortex were significantly lower in DS than in controls. Compared with EOAD, 5-HT levels in DS+AD were significantly lower in the amygdala and basal ganglia (caudate nucleus, globus pallidus, and putamen) and higher in the (pre)frontal cortex and cerebellum. In comparison with EOAD, 5-HIAA was consistently lower in DS+AD, namely in cortical areas (BA9/10/46, BA22), limbic system (amygdala, hippocampus, BA11/12, cingulate gyrus, and thalamus), the basal ganglia (caudate nucleus, globus pallidus, and putamen), and the cerebellum. Similarly, the 5-HIAA:5-HT ratio was reduced in the BA9/10/46, BA22, BA11/12, and cerebellum in DS+AD versus EOAD, thus indicating an overall decreased serotonergic turnover in DS+AD. In summary, a serotonergic deficit became apparent in DS+AD, with a pronounced overall reduction in 5-HIAA levels (and thus a reduced 5-HIAA:5-HT ratio) as compared with EOAD.

Finally, the HVA:5-HIAA ratio, indicating serotonergic inhibition on dopaminergic neurotransmission, clearly differed between groups. Apart from a significantly higher HVA:5-HIAA ratio in the cingulate gyrus in DS (vs. controls), significance was, again, observed for the DS+AD versus EOAD comparison. The ratio was invariably higher in DS+AD for cortical regions (BA9/10/46 and BA22), limbic system (amygdala, hippocampus, BA11/12, and cingulate gyrus), and the cerebellum, suggestive of a reduced serotonergic inhibition on the dopaminergic system.

3.2. Monoaminergic characterization of (paired) CSF/plasma samples {#sec3.2}
------------------------------------------------------------------

Samples of 225 DS individuals were included in analysis ([Fig. 1](#fig1){ref-type="fig"}). Paired samples were available for 68 individuals and plasma-only samples for 157 cases. [Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}, respectively, show the study group characteristics and monoaminergic concentrations. The accompanying ratios are provided in the supplementary material, [Supplementary Table 4](#appsec1){ref-type="sec"}. Remarkably, CSF/plasma concentrations did not differ between the three groups apart from DOPAC levels in CSF (medication-free subpopulation) and plasma (total population and medication-free subpopulation). DOPAC levels were consistently higher in DS+AD compared with DS (CSF medication-free, *P* = .001; plasma total, *P* \< .001; and plasma medication-free, 0.002) but did not differ for the DS versus DS+pAD and DS+pAD versus DS+AD comparisons. Similarly, plasma HVA (total), plasma 5-HIAA (total), and CSF DOPAC:DA (medication-free) were higher in DS+AD versus DS. In contrast, CSF HVA:5-HIAA (total) was decreased in DS+AD. Moreover, DA (r = −0.31, *P* = .012), DOPAC (r = +0.71, *P* \< .001), MHPG (r = +0.70, *P* \< .001), and adrenaline (r = +0.49, *P* \< .001) correlated significantly in CSF and plasma (paired samples, total population). Groups differed in age with DS+AD logically being the oldest. DOPAC (CSF, r = +0.362, *P* = .002; plasma, r = +0.386, *P* \< .001), HVA (plasma, r = +0.169, *P* = .011), and 5-HIAA (CSF, r = +0.365, *P* = .002; plasma, r = +0.345, *P* \< .001) correlated significantly with age. After exclusion of individuals younger than 45 years, that is, resembling the elderly DS cohort in our previously published serum study [@bib12], comparison between DS (CSF/plasma, n = 8; plasma-only, n = 34), DS+pAD (CSF/plasma, n = 11; plasma-only, n = 31), and DS+AD (CSF/plasma, n = 16; plasma-only, n = 38) yielded no significant monoaminergic differences, again suggesting that DOPAC changes most likely relate to aging rather than dementia status.Table 3Characteristics of CSF/plasma study groupsCharacteristicsNo dementia (DS, n = 149)Prodromal AD (DS+pAD, n = 36)Diagnosed AD dementia (DS+AD, n = 40)*P* valueAge (median; min.--max.)36.9 (19.2--61.2)^a,b^49.8 (37.7--59.4)^a,c^55.1 (42.1--69.2)^b,c^\<.001Gender (N male and %)82 (55.0)16 (44.4)25 (62.5)n.s.*APOE* status1 (ε2/2), 15 (ε2/3), 2 (ε2/4), 106 (ε3/3), 23 (ε3/4), 2 (ε4/4)1 (ε2/2), 6 (ε2/3), 21 (ε3/3), 8 (ε3/4)1 (ε2/3), 1 (ε2/4), 30 (ε3/3), 8 (ε3/4)n.s.Levothyroxine (%)61 (40.9)12 (33.3)14 (35.0)n.s.Any psychoactive drugs (%)56 (37.6)19 (52.8)24 (60.0)n.s. Antidepressants36 (24.2)11 (30.6)9 (22.5)n.s. Antiepileptics13 (8.7)7 (19.4)10 (25.0).014 Antipsychotics20 (13.4)8 (22.2)13 (32.5)n.s. Anxiolytics14 (9.4)3 (8.3)8 (20.0)n.s. Antidementia1 (0.7)1 (2.8)5 (12.5).002[^5][^6]Table 4Comparison of CSF/plasma concentrations between the groupsCompoundCSF or plasmaTotal or medication freeNDSDS+pADDS+AD*P* valueNACSFTotal37/13/182.8 (0.9--5.5)1.4 (0.6--4.9)1.8 (0.8--5.6)n.s.Medication free21/7/102.8 (1.0--6.9)1.4 (0.6--4.7)1.4 (0.8--5.5)n.s.PlasmaTotal145/35/370.4 (0.2--0.9)0.6 (0.2--0.9)0.6 (0.4--1.1)n.s.Medication free90/16/150.5 (0.2--1.0)0.4 (0.1--0.7)0.4 (0.2--1.0)n.s.AdrenalineCSFTotal35/13/160.5 (0.3--0.9)0.7 (0.3--1.3)0.4 (0.3--1.2)n.s.Medication free20/7/100.7 (0.3--1.0)0.8 (0.2--2.1)0.4 (0.4--1.2)n.s.PlasmaTotal147/35/392.9 (1.9--4.2)2.6 (1.9--4.0)3.3 (1.4--4.3)n.s.Medication free92/17/162.9 (2.0--4.0)3.0 (2.0--4.2)2.7 (1.2--3.9)n.s.MHPGCSFTotal37/13/1830.2 (21.5--44.6)24.0 (18.8--40.0)22.4 (19.6--46.0)n.s.Medication free21/7/1031.1 (21.8--45.0)24.0 (15.9--41.1)28.5 (20.7--43.4)n.s.PlasmaTotal149/36/4076.2 (51.2--102.4)70.9 (50.4--111.6)75.6 (55.3--114.4)n.s.Medication free93/17/1677.3 (51.5--100.6)70.4 (45.5--119.3)63.0 (47.9--107.5)n.s.DACSFTotal37/13/180.6 (0.4--0.9)0.5 (0.2--0.7)0.6 (0.3--1.2)n.s.Medication free21/7/100.6 (0.4--0.9)0.6 (0.3--1.0)0.8 (0.4--1.3)n.s.PlasmaTotal149/35/400.5 (0.3--1.0)0.5 (0.3--1.1)0.7 (0.3--1.3)n.s.Medication free93/16/160.5 (0.3--1.0)0.6 (0.4--1.1)0.7 (0.4--1.9)n.s.DOPACCSFTotal37/13/180.6 (0.4--1.3)1.2 (0.6--2.7)1.7 (0.7--3.3)*.033*Medication free21/7/100.5 (0.4--1.0)^§§^0.9 (0.5--1.5)2.8 (1.1--5.6)^§§^.003PlasmaTotal149/36/402.7 (1.9--4.1)^§§^3.1 (2.6--4.3)4.3 (3.0--6.2)^§§^\<.001Medication free93/17/162.5 (1.9--3.6)^§^3.1 (2.7--3.6)5.3 (2.9--6.2)^§^.004HVACSFTotal37/13/1854.6 (40.5--67.7)55.1 (43.3--74.8)55.3 (33.3--67.3)n.s.Medication free21/7/1056.3 (41.5--64.1)46.5 (35.2--79.5)56.4 (33.1--67.2)n.s.PlasmaTotal149/36/409.4 (7.5--11.6)^§^10.3 (7.4--12.7)10.6 (8.7--15.0)^§^*.039*Medication free93/17/169.5 (7.4--12.2)10.5 (7.6--13.0)9.9 (8.5--14.2)n.s.5-HTCSFTotal11/4/60.1 (0.1--0.2)0.1 (0.1--0.2)0.1 (0.1--0.2)n.s.Medication free6/2/20.1 (0.1--0.2)0.1 (0.1--)0.1 (0.0--)n.s.PlasmaTotal149/36/409.5 (3.9--20.3)11.1 (2.4--20.8)9.7 (5.2--17.2)n.s.Medication free93/17/1612.4 (7.1--25.0)17.3 (8.0--28.6)10.6 (8.4--20.7)n.s.5-HIAACSFTotal37/13/1824.9 (18.1--28.9)26.5 (21.5--35.4)28.9 (23.2--34.3)n.s.Medication free21/7/1026.6 (22.6--29.7)26.5 (22.0--36.1)33.2 (25.2--38.4)n.s.PlasmaTotal149/36/404.5 (3.7--5.4)^§^4.7 (4.2--5.7)5.0 (4.1--6.6)^§^*.020*Medication free93/17/164.5 (3.6--5.4)5.3 (4.2--6.5)4.9 (3.6--6.7)n.s.[^7][^8]

4. Discussion {#sec4}
=============

Monoaminergic profiles were evaluated in 15 postmortem brain regions and (paired) CSF/plasma samples. In brain, pronounced noradrenergic, dopaminergic, and serotonergic differences were found for DS+AD versus EOAD and to a lesser extent for DS versus controls (primarily decreased MHPG levels), but not for DS versus DS+AD. Similarly, CSF/plasma concentrations were virtually unaltered between the diagnostic DS groups.

In AD, studies have demonstrated LC neuronal loss and reduced NA levels [@bib21], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39]. Noradrenergic abnormalities have been implicated in DS too [@bib40]. Here, we demonstrate that the noradrenergic system was more severely impacted in DS+AD versus EOAD and to a lesser extent in DS versus non-DS controls. NA, MHPG, and the MHPG:NA ratio were significantly reduced in most brain areas, but not in the basal ganglia, which is in accordance with the modest noradrenergic innervation of the basal ganglia [@bib35]. These results are also in agreement with earlier studies reporting AD-related loss of LC neurons [@bib21], [@bib22], [@bib23], [@bib36] and reduced NA levels in various brain regions in DS+AD compared with controls [@bib16], [@bib17], [@bib18], [@bib19], [@bib20]. Our results demonstrate that MHPG concentrations were most severely impacted in DS+AD (even more than in EOAD), but also in DS, thus already before the neuropathological criteria for AD were met.

DA is produced in the SN and ventral tegmental area (VTA). In AD, a variable SN neuronal loss and diminished DA levels have been described [@bib41], [@bib42]. Whereas previous studies did not report evident dopaminergic alterations in DS [@bib16], [@bib18], we found significantly increased DA levels (and thus decreased HVA:DA and DOPAC:DA ratios) in cortical areas, limbic regions and cerebellum, and a general decrease in DA and HVA levels in the basal ganglia. Indeed, lower DA levels in the caudate nucleus have been reported in DS+AD versus EOAD and age-matched controls [@bib20]. Ascending dopaminergic projections are subdivided into the nigrostriatal (from SN to striatum), mesolimbic (from VTA to limbic system), and mesocortical (from VTA to cortex) pathways [@bib35]. Previously, a mild cell loss (though often not significant) in the SN, but also in the VTA, was found in DS+AD compared with controls or younger counterparts [@bib23], [@bib36], [@bib43], [@bib44]. Our results may suggest a more severe impairment of the nigrostriatal pathway (reduced DA levels in caudate and SN), whereas the mesolimbic and mesocortical pathways seem to be somewhat overactive, possibly as a compensatory mechanism.

Concerning the serotonergic system, neuronal loss in the dorsal raphe nuclei (5-HT production site) and reduced levels of 5-HT and 5-HIAA in various brain regions have been reported in AD and DS [@bib16], [@bib17], [@bib18], [@bib35], [@bib36], [@bib37], [@bib39], [@bib45]. Compared with EOAD, we observed an even more severe serotonergic impairment in DS+AD, presenting decreased 5-HIAA levels in 11 brain regions, while 5-HT was reduced in the amygdala and basal ganglia but increased in the (pre)frontal cortex and cerebellum.

Interestingly, the DS and DS+AD groups showed remarkably similar monoaminergic profiles, although both groups had different AD neuropathologic changes (low vs. high). Importantly, the four DS cases with low AD neuropathologic change already presented high amyloid burden ("ABC scoring system" [@bib25]: A2,B1,C2; A3,B1,C1; A3,B0,C0, and A3,B0,C0, respectively). The third copy of the *APP* gene in DS causes very early Aβ overproduction and accumulation. Deposition of Aβ plaques occurs at ages as early as 12 years and precedes tau pathology by many years [@bib4]. Previously, noradrenergic and serotonergic depletion was found to be more severe in EOAD (mutations in *APP* or *PSEN1/2*, promoting the amyloidogenic pathway) than in late-onset AD [@bib38]. Inverse relations between Aβ accumulation and, respectively, NA, DA, and 5-HT signaling have been described [@bib35], [@bib46]. This may suggest that the monoaminergic system is particularly affected by (early) Aβ pathology, being altered long before full-blown AD pathology is present. For a comprehensive summary about the pathophysiological link between monoaminergic alterations and AD pathology, see the review by Trillo et al. [@bib35].

In the context of abnormal brain development, monoamines were quantified in the frontal cortex of fetal DS tissue (20 weeks) compared with controls. DA, 5-HT, and 5-HIAA levels were significantly reduced in DS [@bib47]. This suggests that monoamines are already impacted by trisomy 21 itself, which may be further impaired by progressive Aβ pathology during life. Compared with age-matched controls, smaller brain volumes were found in DS, among others of (pre)frontal cortex, hippocampus, brainstem and cerebellum [@bib48], [@bib49], [@bib50]. Fewer neurons (cortical dysgenesis), altered neuronal distribution, and reduced synaptic density were described in DS as well [@bib49]. Consequently, the compensatory reserve is likely to be lower, which could result in a particularly early vulnerability (functional impact) to additional neuropathology. To differentiate between the alterations caused by trisomy 21 and AD pathology, respectively, future monoaminergic studies should include DS samples without early Aβ plaque load. In the present study, we were unable to collect more than four such cases (limiting the generalizability of the findings in this group) because inclusion of DS cases in brain banks, those without pathology in particular, is very limited. In fact, the 21 cases analyzed here were obtained by three large brain banks in a timeframe of 25 years. Contemporary standardized (multicenter) brain banking efforts for DS are thus imperative [@bib51], [@bib52], focusing, among others, on the collection of tissues with short(er) PMDs and good clinical documentation. Although our main findings did not appear to be evidently impacted by PMDs or psychoactive medication use, such effects cannot be fully ruled out because of the unavailability of DS tissue with low PMDs and no psychoactive medication use.

The apparent lack of monoaminergic changes between DS and DS+AD in the brain was also reflected in CSF/plasma. The CSF/plasma groups were distinguished based on a clinical dementia diagnosis, whereas from a neuropathological perspective, the (amyloid) pathology is likely to be quite comparable. In future studies, it would be useful to relate monoaminergic values in DS to (in vivo) pathologic staging, such as the CSF "AD profile" [@bib11] or positron emission tomography of Aβ/tau [@bib5]. Furthermore, mounting evidence indicates an important role of neuroinflammation in the pathogenesis of AD (in DS) [@bib53], and it would thus be valuable to look further than Aβ and tau pathology and examine the role of neuroinflammatory processes in monoaminergic alterations as well.

Surprisingly, the CSF/plasma results did not reflect earlier results obtained in serum [@bib12]. Whereas MHPG, for instance, was evidently decreased in DS+AD serum, MHPG levels were virtually unaltered in CSF/plasma. This raises the question what causes this apparent discrepancy. Our methodology has been validated [@bib30], and the reported values have orders of magnitude comparable to earlier studies [@bib14], [@bib15], [@bib54]. The---likely multifactorial---answer remains to be elucidated, including the effect of (alterations in) peripheral determinants, such as non-brain sources of catecholamines (e.g., the sympathetic nervous system is the main source of peripheral NA) and enzymes involved in catecholaminergic turnover [@bib55], as well as (pre)analytical variables. O\'Bryant et al. (2015) addressed variables that can impact findings in blood, including controllable variables (e.g., fasting status, tube type, centrifugation parameters, time from collection to freezing, and freezing temperature) and uncontrollable variables (e.g., diet, activity level, comorbidities, and medication). In particular, serum versus plasma, type of needle, additive in the collection tubes, and presence of hemolysis may influence the stability and detectability of biomarkers [@bib56]. In CSF, similar variables may impact biomarker levels [@bib57], [@bib58]. Indeed, a few variables differ identifiably between our serum and plasma studies, such as fasting status, storage temperature, and storage time. Retrospectively identifying the cause of the discrepancy is virtually impossible. New initiatives should, therefore, systematically study the effect of these variables on monoaminergic concentrations.

In conclusion, this study is the first to comprehensively examine monoaminergic alterations in a unique collection of postmortem brain regions and (paired) CSF/plasma samples of DS individuals. Despite various limitations described previously, brain samples of DS+AD (vs. EOAD) revealed generalized impairments in the noradrenergic and serotonergic systems (overall decrease) and a bidirectional dopaminergic change. For DS (vs. controls), significantly decreased MHPG levels were noted, though to a lesser extent than for DS+AD (vs. EOAD). DS and DS+AD groups showed remarkably similar monoaminergic profiles in the brain. CSF/plasma concentrations did not differ between the diagnostic DS groups either. The underlying cause for the discrepancy with earlier serum findings remains unclear and requires further study. To confirm whether the more profound monoaminergic alterations in DS (vs. non-DS) are indeed due to early Aβ accumulation, (longitudinal) studies using positron emission tomography imaging of monoamines might provide a new avenue. For instance, neuroimaging of NA transporters in LC and key projection areas using \[^11^C\]methylreboxetine [@bib59] in relation to amyloid deposition (e.g. \[^11^C\]Pittsburgh compound B) may be of utmost importance in this respect. Moreover, to further investigate disease progression, it would be valuable to relate monoaminergic concentrations to CSF/plasma levels of Aβ and tau within individuals, for instance to the CSF AD profile (low Aβ42, high total-tau, and high phosphorylated-tau) [@bib11].Research in Context1Systematic review: Alterations in monoamine neurotransmitters and metabolites have been implicated in Alzheimer\'s disease (AD) and Down syndrome (DS). However, monoaminergic profiles have not been extensively studied in cerebrospinal fluid (CSF) and postmortem brain samples of DS with/without AD.2Interpretation: This is the first study to comprehensively characterize DS samples with regard to AD diagnosis. In CSF/plasma, monoaminergic levels were not related to the clinical status of dementia in DS. In brain, evident noradrenergic and serotonergic deficits were found in DS+AD versus early-onset AD patients, and to a lesser extent in DS versus non-DS healthy controls. Our results reveal a rather similar monoaminergic profile in both DS and DS+AD, possibly caused by early trisomy 21--related accumulation of amyloid β (Aβ).3Future directions: Positron emission tomography studies of monoaminergic neurotransmission may reveal whether monoaminergic impairment in DS relates to early Aβ accumulation. Longitudinal studies in relation to Aβ imaging would be of utmost importance.
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[^1]: Abbreviations: AD, Alzheimer\'s disease; BA, Brodmann area; DS, Down syndrome without neuropathologic AD diagnosis; DS+AD, Down syndrome with neuropathologic AD diagnosis; EOAD, early-onset Alzheimer\'s disease; n.s., not significant.

[^2]: NOTE. Gender and medication use were compared with Fisher\'s exact test. Kruskal-Wallis tests were performed to compare ages and postmortem delays between the groups. Post hoc Mann-Whitney *U* tests were performed to identify significant group differences (*P* \< .015): (a) DS vs. DS+AD; (b) DS vs. EOAD; (c) DS vs. controls; (d) DS+AD vs. EOAD; (e) DS+AD vs. controls.

[^3]: Abbreviations: AD, Alzheimer\'s disease; BA, Brodmann area; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; DA, dopamine; DS, Down syndrome without neuropathologic AD diagnosis; DS+AD, Down syndrome with neuropathologic AD diagnosis; DOPAC, 3,4-dihydroxyphenylacetic acid; EOAD, early-onset Alzheimer\'s disease; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline; n.s., not significant.

[^4]: NOTE. Monoamines and metabolites (ng/g tissue) are expressed as median (50%) with the interquartile range (25%--75%) between brackets. Kruskal-Wallis tests were used to compare the four groups. If *P* \< .05, post hoc Mann-Whitney *U* tests were performed. After all analyses had been conducted, we accounted for multiple comparisons by performing the Benjamini-Hochberg procedure. Here, we provide *P* values (Kruskal-Wallis) that remained significant after correction (*P* \< .015). Those in italics are no longer regarded significant but are nevertheless provided since the post hoc Mann-Whitney *U* tests remained significant in the Benjamini-Hochberg procedure. Post hoc comparisons were performed for DS vs. controls (^\#^*P* \< .015) and DS+AD vs. EOAD (^∗^*P* \< .015; ^∗∗^*P* \<.001). The accompanying ratios and the nonsignificant comparisons are provided in the supplementary material ([Supplementary Tables 1-3](#appsec1){ref-type="sec"}).

[^5]: Abbreviations: *APOE*, apolipoprotein E gene; DS, Down syndrome without (clinical) dementia; DS+AD, Down syndrome with diagnosed AD dementia; DS+pAD, Down syndrome with prodromal AD; n.s., not significant.

[^6]: NOTE. Age at the moment of sampling is provided as median with range (minimum--maximum). The Kruskal-Wallis test was performed to compare ages between groups. Post hoc Mann Whitney *U* tests were performed to identify significant group differences (*P* \< .015): (a) DS vs. DS+pAD; (b) DS vs. DS+AD; and (c) DS+pAD vs. DS+AD. Gender, *APOE* status, and medication use were compared using Pearson\'s χ^2^ test or Fisher\'s exact test.

[^7]: Abbreviations: 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; AD, Alzheimer\'s disease; CSF, cerebrospinal fluid; DA, dopamine; DS, Down syndrome without (clinical) dementia; DS+pAD, Down syndrome with prodromal AD; DS+AD, DS with diagnosed AD dementia; DOPAC, 3-4-dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline; n.s., not significant.

[^8]: NOTE. Concentrations of monoamines and metabolites (ng/ml) are expressed as median (50%) with the interquartile range (25%--75%) between brackets. The number (N) of samples is provided as certain compounds were not detectable in all samples. Kruskal-Wallis tests were performed to compare the three groups. If *P* \< .05, post hoc Mann-Whitney *U* tests were performed. After all analyses had been conducted, we accounted for multiple comparisons by performing the Benjamini-Hochberg procedure. The *P* values in italics are no longer regarded significant but are nevertheless provided since the post hoc Mann-Whitney *U* tests remained significant in the Benjamini-Hochberg procedure. Post hoc comparisons were performed for DS vs. DS+pAD, DS vs. DS+AD (^§^*P* \<.015 and ^§§^*P* \<.001) and DS+pAD vs. DS+AD. The accompanying ratios are provided in the supplementary material ([Supplementary Table 4](#appsec1){ref-type="sec"}).
